InnoCare Pharma Shares Surge Over 8% After First Patient Dosed with Novel CDH17-Targeting ADC ICP-B208

Beijing InnoCare Pharma Tech Co., Ltd. just moved a step closer to cracking a target that has eluded drugmakers for years. On July 6, the Hong Kong-listed biotech announced that its novel antibody-drug conjugate ICP-B208 has dosed its first patient—a milestone that sent shares surging more than 8% in early trading.

The move puts InnoCare at the forefront of a crowded race to develop therapies against CDH17, a protein found on the surface of tumor cells that has emerged as one of the most promising new targets in oncology. As of now, no CDH17-targeting ADC has won regulatory approval anywhere in the world.

A New Weapon Against GI Cancers

ICP-B208 is built on InnoCare's proprietary ADC platform. The drug pairs a humanized anti-CDH17 antibody with a potent payload developed in-house, linked by a protease-cleavable connector designed to home in on cancer cells while sparing healthy tissue.

CDH17 belongs to the cadherin family of proteins and plays a key role in tumor cell proliferation, migration and metastasis. The protein is overexpressed in a range of gastrointestinal solid tumors—including colorectal, gastric, pancreatic and biliary cancers—making it an attractive target for drug developers hunting for treatments in some of the deadliest cancers.

Market Reacts

Investors took notice. InnoCare's Hong Kong shares (09969.HK) jumped 8.72% to HK$14.2 as of the latest trading data, with turnover reaching HK$45.11 million. The first-patient dosing marks a critical de-risking moment for the program, validating InnoCare's ADC platform and its bet on CDH17 as a viable target.

The company is positioning itself in a field where several biotechs are circling similar targets, but the absence of any approved CDH17-directed therapy underscores both the scientific challenge and the potential commercial upside for whoever crosses the finish line first.

For InnoCare, the first patient is just the beginning. The real test will come as the company moves through clinical trials, where the drug's safety and efficacy will determine whether CDH17 can become the next big thing in cancer therapy—or another promising target that failed to deliver.